양극성 장애 시장 규모, 점유율, 성장 분석 : 유형별, 약물 종류별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Bipolar Disorder Market Size, Share, Growth Analysis, By Type, By Drug Class, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1630624
리서치사:SkyQuest
발행일:2025년 01월
페이지 정보:영문 157 Pages
라이선스 & 가격 (부가세 별도)
한글목차
양극성 장애 세계 시장 규모는 2023년에 53억 6,000만 달러로 평가되며, 2024년에는 54억 9,000만 달러에서 2032년에는 66억 4,000만 달러로 성장할 것으로 예상되며, 예측 기간(2025-2032년) 동안 연평균 2.4%로 성장할 것으로 예상됩니다.
조울증은 조증과 우울증을 포함한 극단적인 기분 변화를 특징으로 하며, 현재 양극성 장애로 알려져 있습니다. 이 질환은 유전적 소인이 중요한 역할을 하며, 단일 원인 인자가 아닌 여러 유전자가 관여합니다. 양극성 장애는 주로 양극성 장애 I, 양극성 장애 II, 주기성 장애의 세 가지 유형이 있습니다. 흥미롭게도 인도의 양극성 장애의 평생 위험도는 0.1%에 불과하지만 미국은 4.4%로 상당히 높습니다. 양극성 장애 치료 시장은 인식 개선 캠페인의 증가, 정확한 기분 평가 기술의 발전, 발병률의 증가로 인해 확대되고 있습니다. 또한, 삼환계 항우울제의 부작용으로 인해 삼환계 항우울제 사용이 감소하고 있으며, 보다 효과적인 치료 옵션으로 전환되고 있습니다.
목차
소개
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터 방법
시장 규모 예측
시장 가정과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porters 분석
주요 시장 인사이트
핵심성공요인
경쟁 정도
주요 투자 기회
시장 생태계
시장 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
규제 상황
사례 연구
고객과 구매 기준 분석
양극성 장애 시장 규모 : 유형별
시장 개요
기분안정제
항경련제
항정신병제
항우울제
항불안제
기타 유형
양극성 장애 시장 규모 : 약물 종류별
시장 개요
선택적 세로토닌 재흡수 억제제
세로토닌 노르에피네프린 재흡수 억제제
삼환계 항우울제
모노아민 산화효소 억제제
벤조디아제핀
베타 차단제
기타 약물 클래스
양극성 장애 시장 규모 : 유통 채널별
시장 개요
병원 약국
소매 약국
온라인 약국
양극성 장애 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5개사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채용한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 개요
제품 포트폴리오 분석
부문별 점유율 분석
매출 전년비 비교(2022-2024)
주요 기업 개요
Eli Lilly and Company(USA)
GlaxoSmithKline plc(UK)
Pfizer Inc.(USA)
AstraZeneca plc(UK)
Otsuka Holdings Co., Ltd.(Japan)
H. Lundbeck A/S(Denmark)
Teva Pharmaceutical Industries Ltd.(Israel)
Takeda Pharmaceutical Company Limited(Japan)
AbbVie Inc.(USA)
Novartis International AG(Switzerland)
Merck & Co., Inc.(USA)
Bristol Myers Squibb Company(USA)
Alkermes plc(Ireland)
Mylan N.V.(USA)
Neurocrine Biosciences, Inc.(USA)
Vanda Pharmaceuticals Inc.(USA)
Sunovion Pharmaceuticals Inc.(USA)
Intra-Cellular Therapies, Inc.(USA)
Acadia Pharmaceuticals Inc.(USA)
Reviva Pharmaceuticals Holdings, Inc.(USA)
결론과 추천사항
ksm
영문 목차
영문목차
Global Bipolar Disorder Market size was valued at USD 5.36 billion in 2023 and is poised to grow from USD 5.49 billion in 2024 to USD 6.64 billion by 2032, growing at a CAGR of 2.4% during the forecast period (2025-2032).
Manic depression, now known as bipolar disorder, is characterized by extreme mood fluctuations, including manic and depressive episodes. Genetic predisposition plays a significant role in this condition, with multiple genes involved rather than a single causative factor. There are three main types of bipolar disorder: bipolar I, bipolar II, and cyclothymic disorder. Interestingly, while India's lifetime risk for bipolar disorder is just 0.1%, the United States has a significantly higher prevalence at 4.4%. The market for bipolar disorder treatment is expanding, driven by increasing awareness campaigns, advancements in technology for accurate mood assessment, and the rising incidence of the disorder. Additionally, the use of tricyclic antidepressants is declining due to their side effects, leading to a shift toward more effective treatment options.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bipolar Disorder market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Bipolar Disorder Market Segmental Analysis
Global Bipolar Disorder Market is segmented by Type, Drug Class, Distribution Channel and region. Based on Type, the market is segmented into Mood stabilizer, Anticonvulsants, Antipsychotic drugs, Antidepressant drugs, Antianxiety drugs and Other Types. Based on Drug Class, the market is segmented into Selective serotonin reuptake inhibitor, Serotonin norepinephrine reuptake inhibitor, Tricyclic antidepressant drugs, Monoamine oxidase inhibitors, Benzodiazepines, Beta blockers and Other Drug Classes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Bipolar Disorder Market
The global bipolar disorder market is expected to witness significant growth driven by a strong focus on enhancing product offerings and an increasing prevalence of mental health issues. Key players in the industry are actively expanding their product portfolios, which includes the introduction and approval of new pharmaceuticals specifically targeting bipolar disorder. For instance, the FDA recently approved Allergan plc and Gedeon Richter plc's supplemental new drug application for VRAYLAR (cariprazine), underscoring the commitment to advancing treatment options. Furthermore, rising awareness initiatives and government efforts aimed at highlighting the impacts of bipolar disorder, alongside a growing demand for effective antidepressants, are contributing to a reduction in the overall burden of this mental health condition.
Restraints in the Global Bipolar Disorder Market
The Global Bipolar Disorder market faces significant challenges due to several restraints that could impede its growth. A prominent issue is the insufficient availability of effective medications and suitable treatment protocols, which complicates management of the condition. Additionally, the expiration of patents for major drugs, such as Latuda, Abilify Maintena, and Risperdal Consta, poses further limitations, potentially leading to increased competition from generic alternatives like lithium. Moreover, the absence of reliable diagnostic methods and the adverse side effects associated with existing treatments exacerbate these market constraints. However, advancements in drug combination therapies present potential avenues for future growth within this sector.
Market Trends of the Global Bipolar Disorder Market
The global bipolar disorder market is witnessing significant growth, driven by the rising prevalence of mental health disorders, particularly among children and adolescents. Increased awareness and reduced stigma surrounding mental illnesses have led to higher diagnosis rates of bipolar disorder, prompting a surge in demand for effective treatment options. Advances in pharmacotherapy and psychotherapy, combined with the integration of digital health solutions, are further transforming the therapeutic landscape. Additionally, greater emphasis on personalized medicine and early intervention strategies is anticipated to enhance patient outcomes, solidifying bipolar disorder as a critical area within the broader mental health market.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Customer & Buying Criteria Analysis
Global Bipolar Disorder Market Size by Type & CAGR (2025-2032)
Market Overview
Mood stabilizer
Anticonvulsants
Antipsychotic drugs
Antidepressant drugs
Antianxiety drugs
Other Types
Global Bipolar Disorder Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Selective serotonin reuptake inhibitor
Serotonin norepinephrine reuptake inhibitor
Tricyclic antidepressant drugs
Monoamine oxidase inhibitors
Benzodiazepines
Beta blockers
Other Drug Classes
Global Bipolar Disorder Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Bipolar Disorder Market Size & CAGR (2025-2032)
North America (Type, Drug Class, Distribution Channel)
US
Canada
Europe (Type, Drug Class, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Type, Drug Class, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Type, Drug Class, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Type, Drug Class, Distribution Channel)
